Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: A tale of two complexes

Advances in Biological Regulation

Volumn 57, Issue , 2015, Pages 64-74

  Jhanwar Uniyal, Meena ^a   Gillick, John L ^a   Neil, Jayson ^a   Tobias, Michael ^a   Thwing, Zachary E ^a   Murali, Raj ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

4E BP1; GBM; MTOR; MTORC1; MTORC2; S6K

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; TOR COMPLEX 2;

ALLOSTERISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL SURVIVAL; DIET THERAPY; DRUG EFFECTS; ENZYME ACTIVE SITE; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MITOSIS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALLOSTERIC REGULATION; ANTIBIOTICS, ANTINEOPLASTIC; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MITOSIS; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84920811657     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2014.09.004     Document Type: Review

References (61)

1. Albert L., Karsy M., Murali R., Jhanwar-Uniyal M. Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme. Cancer Genomics Proteomics 2009, 6:255-261.
2. Brescia P., Ortensi B., Fornasari L., et al. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 2013, 31(5):857-869.
3. Castilho R.M., Squarize C.H., Chodosh L.A., et al. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 2009, 5(3):279-289.
4. Chan J.A., Zhang H., Roberts P.S., et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. JNeuropathol Exp Neurol 2004, 63(12):1236-1242.
5. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investig New Drugs 2005, 23:357-361.
6. Chen C.H., Sarbassov dos D. The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. JBiol Chem 2011, 286(46):40386-40394.
7. Choi J., Chen J., Schreiber S.L., et al. Structure of the FKBP12-rapamycin complex interacting with the biding domain of human FRAP. Science 1996, 273(5272):239-242.
8. Cloughesy T.F., Yoshimoto K., Nghiemphu P., et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5:e8.
9. Dancey J.E., Curiel R., Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 2009, 36(Suppl. 3):S46-S58.
10. Darb-Esfahani S., Faggad A., Noske A., et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade invivo and link with response to rapamycin treatment invitro. JCancer Res Clin Oncol 2009, 135(7):933-941.
11. Dorrello N.V., Peschiaroli A., Guardavaccaro D., et al. S6K1- and beta TRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314(5798):467-471.
12. Ducker G.S., Atreya C.E., Simko J.P., et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014, 33:1590-1600.
13. Eshleman J.S., Carlson B.L., Mladek A.C., Kastner B.D., Shide K.L., Sarkaria J.N. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002, 62:7291-7297.
14. Feldman M.E., Apsel B., Uotila A., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
15. Fragoso R., Barata J.T. PTEN and leukemia stem cells. Adv Biol Regul 2014, 56:22-29.
16. Friedman M.D., Jeevan D., Tobias M., et al. Targeting cancer stem cells of glioblastoma multiforme using mTOR inhibitors and differentiating agent all-trans retinoic acid. Oncol Rep 2013, 30(4):1645-1650.
17. Galanis E., Buckner J.C., Maurer M.J. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. JClin Oncol 2005, 23(23):5294-5303.
18. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
19. Guertin D.A., Stevens D.M., Thoreen C.C., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006, 11:859-871.
20. Gulati N., Karsy M., Albert L., Murali R., Jhanwar-Uniyal M. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol 2009, 35:731-740.
21. Harrington L.S., Findlay G.M., Gray A., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. JCell Biol 2004, 166(2):213-223.
22. Hsu P.P., Kang S.A., Rameseder J., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332(6035):1317-1322.
23. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22(20):7004-7014.
24. Jacinto E., Hall M.N. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003, 4:117-126.
25. Jacinto E., Loewith R., Schmidt A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-1128.
26. Jhanwar-Uniyal M., Albert L., McKenna E., et al. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. Adv Enzyme Regul 2011, 51:164-170.
27. Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing mTOR complexes in regulation of glioblastoma multiforme and its stem cells. Adv Biol Regul 2013, 53:202-210.
28. Kim D.H., Sarbassov D.D., Ali S.M., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
29. Kim D.H., Sarbassov D.D., Ali S.M., et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003, 11:895-904.
30. Knight Z.A., Gonzalez B., Feldman M.E., et al. Apharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125(4):733-747.
31. Kubica N., Crispino J.L., Gallagher J.W., et al. Activation of the mammalian target of rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2Bvarepsilon mRNA translation and protein synthesis. Int J Biochem Cell Biol 2008, 40(11):2522-2533.
32. Laplante M., Sabatini D.M. mTOR signaling. Cold Spring Harb Perspect Biol 2012, 4(2):a011593.
33. Liu P., Guo J., Gan W., et al. Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. Protein Cell 2014, 5(3):171-177.
34. Loewith R., Jacinto E., Wullschleger S., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10(3):457-468.
35. Mangiola A., Lama G., Giannitelli C., et al. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 2007, 13:6970-6977.
36. Matsumoto K., Arao T., Tanaka K., et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009, 69(18):7160-7164.
37. McCord A.M., Jamal M., Shankavaram U.T., et al. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells invitro. Mol Cancer Res 2009, 7(4):489-497.
38. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
39. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
40. Pearce L.R., Sommer E.M., Sakamoto K., et al. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J 2011, 436(1):169-179.
41. Peterson T.R., Laplante M., Thoreen C.C., et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
42. Piccirillo S.G., Combi R., Cajola L., et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 2009, 28:1807-1811.
43. Platet N., Liu S.Y., Atifi M.E., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007, 258(2):286-290.
44. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006, 12(3 Pt 1):860-868.
45. Reardon D.A., Desjardins A., Vredenburgh J.J., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. JNeurooncol 2010, 96(2):219-230.
46. Reiling J.H., Sabatini D.M. Stress and mTORture signaling. Oncogene 2006, 25(48):6373-6383.
47. Riemenschneider M.J., Betensky R.A., Pasedag S.M. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 2006, 66(11):5618-5623.
48. Rosenwald I.B. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 2004, 23(18):3230-3247.
49. Russell R.C., Fang C., Guan K.L. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011, 138(16):3343-3356.
50. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734.
51. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
52. Shimizu T., Tolcher A.W., Papadopoulos K.P., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012, 18(8):2316-2325.
53. Soeda A., Park M., Lee D., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28(45):3949-3959. 10.1038/onc.2009.252.
54. Sokolosky M.L., Stadelman K.M., Chappell W.H., et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011, 2(7):538-550.
55. Tamburini J., Chapuis N., Bardet V., et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008, 111(1):379-382.
56. Volarevic S., Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001, 65:101-127.
57. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51(5):1635-1644.
58. Yu Y., Yoon S.O., Poulogiannis G., et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332(6035):1322-1326.
59. Zeng Z., Sarbassov dos D., Samudio I.J., et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109:3509-3512.
60. Zeppernick F., Ahmadi R., Campos B., et al. StemCell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008, 14(1):123-129.
61. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144(5):757-768.